RFL (Rafael Holdings) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RFL Rafael Holdings Inc RFL
44 GF Score
Price $2.34
GF Value $1.36
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Rafael Holdings Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

RFL
44GF Score
Rafael Holdings Inc RFL
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rafael Holdings (RFL) Overvalued in 2026?

Based on GuruFocus' analysis, Rafael Holdings stock appears to be overvalued. The current stock price of $2.34 is trading 72.1% above its estimated GF Value™ of $1.36. GuruFocus considers Rafael Holdings to be Significantly Overvalued.

Key valuation signals for RFL:

  • Interest Received:
  • GF Value™: $1.36 vs. price of $2.34 (72.1% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the RFL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rafael Holdings Business Description

Address 520 Broad Street, Newark, NJ, USA, 07102
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
44GF Score

Get the complete analysis for RFL

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$1.36
GF Value